Kornimate/medical-research-clean huggingface dataset:
study to investigate adipocyte cell and lipid turnover in obese adolescents

Conditions: Pediatric Obesity

Summary: insulin resistance is the best predictor of whether the obese adolescent will develop type 2 diabetes. the present studies will focus on determining what might cause fat to accumulate in the subcutaneous fat regions and lead to local inflammation, causing insulin resistance to develop in obese adolescents.

the purpose of this study is to test whether the reduced transcription of key lipogenic/adipogenic genes in abdominal subcutaneous adipose tissue (sat) in obese adolescents with a high vat/sat (visceral adipose tissue/subcutaneous adipose tissue) ratio translates functionally into a reduced in vivo triglyceride (tg) synthesis and adipocyte proliferation, which in turn will contribute to ectopic fat accumulation and insulin resistance (ir). to test whether the storage capacity of gluteal sat is linked to the level of vat/sat fat distribution in obese adolescents. to explore if changes in dietary fat intake (palmitate intake) alters ceramide concentration in both plasma and adipose tissue (at) and the inflammasome complex in the different fat distribution phenotypes and their associations with ir.

Eligibility criteria:
inclusion criteria: * overweight (85-95th% age and gender specific) or obese (\>95th% age and gender specific) * ages 12-18 years * absence of any endocrinopathy * absence of any therapy with medication known to alter glucose metabolism (i.e.: oral steroids, certain psychiatric medications such as xeleca, lithium, paxil) * english speaking subjects exclusion criteria: * any disease known to alter glucose metabolism (t2dm) * diuretic medication * pregnant or breastfeeding * type 1 or 2 diabetes

Keywords: obesity pediatric
efficacy and safety of using combination of 755-nm picosecond alexandrite laser and 2% hydroquinone compared with 2% hydroquinone alone for the treatment of melasma: a randomized split-face controlled trial

Conditions: Melasma

Summary: this study aims to assess the efficacy and safety of using combination of 755-nm picosecond alexandrite laser and 2% hydroquinone compared with 2% hydroquinone alone for the treatment of melasma: a randomized split-face controlled trial


Eligibility criteria:
inclusion criteria: * both male and female age 18-60 years * melasma on both cheeks - epidermal or mixed type * fitzpatrick skin type iii-v exclusion criteria: * history of retinoid or other keratolytic drugs used within 6 months before enrolled * history of keloid * photosensitivity * immunocompromised host
noninvasive diagnosis model for high-risk varices in cirrhosis

Conditions: Varices; Liver Cirrhosis

Summary: this is an observational ambispective cohort study to validate the baveno vi guideline and develop a new diagnostic model to screen high-risk varices (hrv) of liver cirrhosis using ilivtouch.

esophageal variceal bleeding is a common and fatal complication in patients with liver cirrhosis. the diagnosis of high-risk varices (hrv) traditionally depends on gastroscopy, which is expensive and poorly tolerated with patients. baveno vi guideline has put forward a hrv screening model based on liver stiffness and platelet count. this is an observational ambispective cohort study. the retrospective cohort is derived from the previous records of the hospital information system, and the prospective cohort is enrolled prospectively at the local research center when participants meet the inclusion criteria. the purpose of this study is to establish a diagnostic model of hrv in patients with liver cirrhosis according to the liver stiffness value measured by ilivtouch and other laboratory indexes, so as to verify the applicability of baveno vi standard under the condition of ilivtouch and establish a cutoff value that is more suitable for ilivtouch. in addition, this study will try to find some new indexes to further improve the diagnostic efficiency of hrv. the minimum enrolment period is anticipated to be 6 months per center and will be extended if necessary to reach the overall study target.

Eligibility criteria:
inclusion criteria: 1. age 18-75; 2. patients with liver cirrhosis diagnosed by clinical or imaging diagnosis; 3. the interval of ilivtouch and esophagogastroduodenoscopy is no more than 3 months; exclusion criteria: 1. the interval between esophagogastroduodenoscopy and ilivtouch is more than 3 months; 2. any decompensation events (ascites, hepatic encephalopathy or gastroesophageal variceal bleeding) during endoscopy or ilivtouch examination, or during the interval between them; 3. currently taking nonselective beta blocker/ antiplatelet / anticoagulant drugs; 4. hepatocellular carcinoma; 5. after transjugular intrahepatic portosystemic shunt surgery; 6. after liver transplantation. 7. portal-spleen-mesenteric venous thrombosis; 8. patients with splenectomy; 9. bmi ≥ 30; 10. patients with acute active hepatitis or patients with cholestatic hepatitis; 11. iqr/median of liver stiffness measurement \> 30%.

Keywords: diagnostic model high risk varices ilivtouch
a study to evaluate the efficacy and safety of cabergoline compared with placebo for the treatment of rls

Conditions: Restless Legs Syndrome

Summary: the purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (plms) arousl index and sleep efficiency in patients with rls. also, additional objective and subjective sleep parameters and quality of life will be assessed.


Eligibility criteria:
inclusion criteria: * idiopathic rls * moderate to severe symptoms as indicated by an irls total score greater than or equal to 10 and a severity at night score of greater than or equal to 4 * in a baseline polysomnography, patients had to have periodic leg movements during sleep arousal index greater than 5/hour of total sleep time exclusion criteria: * patients suffering from seconadry rls, due to causes such as iron deficiency or renal disease, or suffering from secondary rls while taking drugs suspected of causing secondary forms of rls
changes in incretines, gut hormones and bile acids after roux-en-y gastric bypass

Conditions: Morbid Obesity

Summary: obesity is an increasing world wide problem. moreover, the increase in patients who are considered morbidly obese is even higher (sturm et al, healt aff 2004). conservative approaches such as diets or medication are unsuccessful in the majority of the patients. additionally, (morbid) obesity leads often to cardiovascular diseases, such as hypertension, dyslipidemia and type 2 diabetes (t2dm). when patients need insulin to regulate their glucose levels, their weight is even more difficult to control. therefore, bariatric procedures are increasingly performed, with over 8.000 procedures in the netherlands in 2013. the two most performed types of bariatric surgery in the netherlands are the laparoscopic roux-en-y gastric bypass (lrygb) and the laparoscopic sleeve gastrectomy (lsg). within the lrygb there are different variants available. in a recently initiated randomized controlled trial (rct) from our centre, a comparison between two variants of rygb was performed. in this rct our standard rygb (s-rygb:alimentary limb (al) of 150cm; biliopancreatic limb (bpl) of 75cm) was compared with a rygb with an long bpl (lbplrygb:al of 75cm and a bpl of 150cm). a lbplrygb might improve weight loss and reduction after surgery. the exact mechanism of action is still not fully understood. stomach volume is decreased and satiety levels often increase, probably due to changes in incretin levels. passage of foods through the gastrointestinal tract are altered after rygb. a possible explanation might be found in different levels of incretins (such as glp-1, pyy and ghrelin) and bile acids (fgf-19 and fgf-21) after bariatric surgery.


Eligibility criteria:
inclusion criteria: * general guidelines for bariatric surgery according to fried (fried et al, obes surg 2007). * age \> 18 years * patients must be able to adhere to the study visit schedule and protocol requirements * patients must be able to give informed consent and the consent must be obtained prior to any study procedures * patients who are planned for a lrygb exclusion criteria: * binge-eating or associated eating disorder * active drug or alcohol addiction * pregnancy and when giving breast feeding * a medical history of bariatric surgery * patients with a language barrier which can inhibit patients to follow the correct medical advice * any kind of genetic disorder that can inhibit patients to follow the correct medical advice

Keywords: incretines bile acids gut hormones limb lengths biliopancreatic limb bariatric surgery gastric bypass
histological validation of carotid plaque composition in preoperative imaging

Conditions: Carotid Stenosis

Summary: patients scheduled for carotid endarterectomy undergo preoperative imaging to assess vulnerable plaque. the imaging modalities include (in various combinations at different study sites) 3-dimensional ultrasound, pet/ct imaging with fluorodeoxyglucose, mri (3t)with gadolinium, and contrast ultrasound for assessment of neovascularity of plaques. at surgery the carotid endarterectomy is carried out with en bloc removal of the specimen, which is scanned and stained and assembled into 3d histology.

detailed description: patients will undergo 3d u/s and at least one other imaging method, pet/cta or mri, preoperatively. at some sites, some patients will also have an ultrasound with microbubbles. following surgery, the carotid specimens will be transported to a central pathology lab for microcomputed tomographic imaging and further study. at some sites patients will have a follow-up 3d u/s approximately 1 year after surgery to determine progression of plaque. cain-2 sub-studies: eligible patients may be enrolled into one of the following sub-studies: 1. cain-2 naf pilot characterizing atherosclerotic plaque with sodium fluoride positron emission tomography- a sub-study of the canadian atherosclerosis imaging network (cain project 2), - patients undergo sodium fluoride (naf) pet/ct with cta instead of fdg pet/ct preoperatively. all other imaging and study procedures are carried out as per the cain-2 study. recruitment for this pilot study is complete. 2. cain-2b atherosclerotic plaque imaging using naf and fdg imaging: validation and evaluation of disease progression. a sub-study of the canadian atherosclerosis imaging network (cain-2) histopathology validation study - patients undergo both naf and fdg pet/ct preoperatively. all other imaging and study procedures are carried out as per the cain-2 study. a total of 45 patients will be enrolled in this sub-study. eligibility criteria for the sub-studies is identical to the cain-2 criteria.

Eligibility criteria:
inclusion criteria: * scheduled for carotid endarterectomy; provided informed consent exclusion criteria: * those not eligible for some of the imaging modalities (for example, metal in body, renal dysfunction) are excluded from mri imaging or ct angiography

Keywords: carotid endarterectomy vulnerable plaque ultrasound mri pet/ct
diurnal ramadan fasting on appetite hormone and metabolic profile among lean, obesity, diabetics

Conditions: Fasting; Gut Hormone

Summary: diabetes mellitus individuals are known to have dietary rules, namely regulating the amount, type and time of eating. ramadan fasting seems to be beneficial for people who want to reduce their weight, but it is not easy for diabetic patients. because of its distinctive features, ramadhan induces changes in eating habits, calorie consumption, sleeping patterns, and daily physical activity, which may contribute to changes in hunger-satiety responses and glicemic control. examining changes in gut hormones during ramadan fasting may reveal whether this observance could change glucose metabolism in diabetics without triggering the undesirable effect of gluconeogenesis. the proportions of fat, protein, and carbohydrate in meals vary between outside and within ramadan. alterations in timing and composition meal during ramadan lead to reduced food intake may affect gut hormones and metabolic responses. the aim of this study to determine whether the effect of ramadan fasting differed in people with dm patients, pre-dm and healthy individuals, with respect to gut hormones, body composition, metabolic parameters, and glycemic control

the experimental study was performed during and after ramadan fasting in 2021 (april to may) in semarang, indonesia. the present study was performed using the quasy-experimental method by pre-post measurement of three experimental groups (diabetics, obese and healthy subjects) selected using the purposive sampling methods

Eligibility criteria:
inclusion criteria: * diabetics subjects: glucose fasting plasma \> 200 mg/dl, with aged 35-60 years and body mass index above 25 kg/m; * obese subjects: body mass index above 25 kg/m2 with aged 35-60 years and waist circumference for men \>90 cm, for women \> 80 cm * lean subjects: body mass index below 23.5 kg/m2 with aged 35-60 years and waist circumference for men \<90 cm, for women \< 80 cm exclusion criteria: * experienced weight loss more than 10% from the actual weight in the last three months * consumed medicine or supplement for weight loss diet, •. had the history of evidence of clinical depression, cognitive disorders, heart disease, cancer, liver or renal disease, chronic pulmonary disease, uncontrolled hypertension, physical disability, or other contraindications

Keywords: gut hormones metabolic parameters obesity lean diabetics ramadan fasting
sulfasalazine and endothelial function

Conditions: Coronary Artery Disease

Summary: experimental studies suggest that systemic inflammation leads to endothelial dysfunction and atherosclerosis. this study will examine the effects of the anti-inflammatory drug sulfasalazine on endothelial function in patients with coronary artery disease. subjects will be treated with sulfasalazine or to placebo for six weeks. after a two-week rest period, subjects will cross over to the alternative treatment. endothelium-dependent flow-mediated dilation of the brachial artery will be studied before and after each drug. we hypothesize that anti-inflammatory therapy will reverse endothelial dysfunction in patients with coronary artery disease.


Eligibility criteria:
inclusion criteria: * history of coronary artery disease exclusion criteria: * g6pd deficiency defined by red blood cell g6pd activity assay * sulfa allergy * aspirin allergy * allergy to furosemide (lasix), hydrochlorthiazide, sulfonylureas, acetazolamide (diamox) or other carbonic anhydrase inhibitors * sgot, sgpt, alkaline phosphatase, total bilirubin greater than 2 times the upper limit of normal * wbc less than 4.0 or greater than 11.0 k/ul * platelet count less than 150 k or greater than 450k * hematocrit less than 30% 7 * serum creatinine greater than 1.5 mg/dl * unstable angina or acute mi within 2 weeks * warfarin treatment * immunosuppressive treatment (methotrexate, cyclosporine, etc.) * digoxin treatment * phenytoin (dilantin) treatment * methenamine (mandelamine, urex) treatment * probenecid or sulfinpyrazone (anturane, aprazone) treatment * porphyria * symptomatic gi obstruction * gu obstruction (not including clinical evidence of benign prostatic hypertrophy) * pregnancy
a randomized controlled trial comparing the effectiveness of different treatment options for weight management after discontinuation of semaglutide and tirzepatide (glp1 transition trial)

Conditions: Obesity; Overweight

Summary: the study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. the primary outcome is absolute and percentage weight change at 12-weeks.


Eligibility criteria:
inclusion criteria: * 18 years or older * previous hx of bmi of \>30 or bmi of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease) * currently taking wegovy, ozempic, mounjaro or zepbound and have been for at least 6 months * at least 15% body weight loss since taking wegovy, ozempic, mounjaro, or zepbound * willing to stop taking their glp-1 medication or is discontinuing due to circumstances such as access, cost, coverage, choice, or any other reason * ability to provide informed consent prior to any trial-related activities * able to read and write in english exclusion criteria: * bmi \<22 kg/m2 * diabetes * previous surgical obesity treatment * currently pregnant or intending to become pregnant during the study * breastfeeding * history of seizures or epilepsy * current opioid use or in acute opioid withdrawal * abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs * history of glaucoma * uncontrolled hypertension * severe renal impairment and/or chronic kidney disease stage iii or gfr \<60 * acute hepatitis or liver failure * acute or chronic metabolic acidosis, including diabetic ketoacidosis * use of antipsychotic medications or opiod analgesics * current or previous history of anorexia or bulimia nervosa * engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight * current ssri, snri, mood stabilizer, amphetamine, or corticosteroid use * current diagnosis of hyper or hypothyroidism or current use of thyroid replacement medicine * current use of beta blockers * current use of depo shot (medroxyprogesterone acetate) for birth control * current diagnosis of cushing's disease or syndrome * current use of monoamine oxidase inhibitors (maois) * known hypersensitivity to bupropion, naltrexone, or metformin * any other reason rendering a participant unsuitable for trial participation, as determined by a clinician or study investigator
study of anti-telomerase t cd4 immunity in metastatic lung cancer

Conditions: Lung Cancer

Summary: increasing evidence suggests that immune responses might be a determining factor in lung cancer tumor progression. the impressive clinical responses obtained with immune checkpoint inhibitors (anti-pd-1/pdl-1, anti-ctla-4) indicate that the presence of preexisting antitumor immune response is required for their efficacy and highlight the critical role of antitumor t cell immunity. recent progress on the fields of tumor immunology underlines the critical role of cd4 helper 1 t lymphocyte (th1) in the control of innate and adaptive anticancer immunity. therefore, monitoring tumor specific th1 response could be relevant in cancer patients. in order to monitor tumor-specific cd4 th1 responses in most cancer patients, the investigators group have previously described novel promiscuous peptides (referred as ucp:universal cancer peptides) derived from human telomerase (tert), a prototype of shared tumor antigen. by using ucp-based immuno-assay, pre-existing ucp-specific th1 responses have been detected in the blood of lung cancer patients (telocap01). the frequency and magnitude of this response were inversely correlate to the disease stage. furthermore, ucp-specific responses were significantly found in patients with low pd1+ and tim3+ t cells. then in telocap02 study, ucp specific th1 immune responses will be evaluated in lung cancer before and after treatment (chemotherapy, immunotherapy).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed nsclc (non small cell lung cancer) or sclc (small cell lung cancer) * stade iiib or metastatic * patient candidate to a first-line therapy * performance status 0, 1 or 2 on the ecog scale * written informed consent exclusion criteria: * history of adjuvant chemotherapy for lung cancer treatment * patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) * prior history of other malignancy except for: basal cell carcinoma of the skin, cervical intra-epithelial neoplasia and other cancer curatively treated with no evidence of disease for at least 5 years * active autoimmune diseases, hiv, hepatitis c or b virus * patients with any medical or psychiatric condition or disease, * patients under guardianship, curatorship or under the protection of justice.
noninvasive cardiac output measurements in patients with pulmonary hypertension undergoing exercise testing

Conditions: Pulmonary Hypertension

Summary: subjects in this study have been diagnosed with pulmonary hypertension and their doctors have referred them for an exercise test as part of their normal, routine care. the exercise test will either be a treadmill test or a 6 minute walk test. during a treadmill test, a patient typically walks on a treadmill while their heart is monitored using an electrocardiogram, which records the electrical activity of the heart through 10 small electrode patches attached to the skin of the chest, arms and legs. additionally, heart rate and blood pressure are monitored throughout the test. a 6-minute walk test requires patients to walk for up to 6 minutes to determine how far they can go in order to measure the heart function related to exercise. the purpose of this study is to measure internal heart pressures using a device called noninvasive cardiac output monitoring (nicom) during an exercise test. normally heart pressures are measured during invasive (meaning that doctors have to go inside the body using a needle or surgery) heart procedures. the nicom device is non-invasive which means the investigators do not have to go inside the body to obtain the heart pressure measurements. in this study, the investigators will evaluate the non-invasive measurements provided by the nicom device during the exercise test and see how it relates to information from some of subjects' past heart procedures. this research is being done to devise better, less invasive ways to assess disease severity, track disease progression and evaluate response to therapy. the nicom device is approved by the us food and drug administration (fda) to measure heart pressures. this device is usually used when a patient can't undergo a right heart catheterization. in this study, the investigators are using the device to gather heart pressure measurements for research during the exercise test that is scheduled as part of the subjects' normal, routine care. the research data is being used to devise better, less invasive ways to assess disease severity, track disease progression and evaluate response to therapy. the nicom device is made by cheetah medical.


Eligibility criteria:
inclusion criteria: * have pulmonary hypertension * undergoing standard of care exercise testing * 18 years or older exclusion criteria: * unable or unwilling to give informed consent

Keywords: to determine the utility of a noninvasive method of measuring cardiac output during exercise testing in patients with ph
evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using sw as medical device

Conditions: Diabetes Mellitus

Summary: a prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using ai medical device

a prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using the swamd medical device and the swamd comparator, when evaluating the patients retinal image

Eligibility criteria:
inclusion criteria: * men and women aged ≥ 40 years * signed informed consent * confirmed type 1 or 2 diabetes mellitus exclusion criteria: * ocular findings that do not allow retinal photography (significant nystagmus, corneal leukoma, dense cataract, hemophthalmus, etc.) * patient has a condition or is in a situation that, in the opinion of the investigator, may bias the results of the study, may significantly interfere with the patient's participation in the investigation, or may result in unproducible photographs of a dilated ocular fundus * patients with restrictions on personal freedom by administrative or legal order